Basilea appoints new Chief Financial Officer

Basilea appoints new Chief Financial Officer

November 04, 2013 01:20 | Source: Basilea Pharmaceutica Ltd.
BASEL, Switzerland, Nov. 4, 2013 (GLOBE NEWSWIRE) --

Basilea Pharmaceutica Ltd. (SIX: BSLN)
announced today the promotion of Mr. Donato Spota to Chief Financial Officer of
the Company, effective today. As a member of the management committee, he will
be responsible for finance, information technology, and internal services. Mr.
Spota has served as Global Head of Finance and Services since February 2013.
Prior to this position, Mr. Spota acted as Head of Basilea's Global Controlling
since 2002.

Ronald Scott, Chief Executive Officer of Basilea, stated: "Donato Spota has been
with the company for over ten years. He has demonstrated exceptional execution
in leading Basilea's finance and controlling functions. He was instrumental in
establishing Basilea's finance organization and has been a key participant in
all our major financing and partnering transactions. I am confident that with
his longstanding financial and operational experience Donato will continue to
significantly contribute to lead our business forward."

Mr. Spota holds a master degree in business administration from the University
of Applied Sciences Nürtingen, Germany and a diploma in information technology
from SFBI (Staatssekretariat für Bildung, Forschung und Innovation),
Switzerland. He has over 16 years of experience as a finance professional in the
pharmaceutical industry, including with F. Hoffmann-La Roche prior to joining

About Basilea

Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland, and listed on
the SIX Swiss Exchange (SIX: BSLN). Through the fully integrated research and
development operations of its Swiss subsidiary Basilea Pharmaceutica
International Ltd., the company focuses on innovative pharmaceutical products in
the therapeutic areas of bacterial infections, fungal infections and oncology,
targeting the medical challenge of rising resistance and non-response to current
treatment options.


This communication expressly or implicitly contains certain forward-looking
statements concerning Basilea Pharmaceutica Ltd. and its business. Such
statements involve certain known and unknown risks, uncertainties and other
factors, which could cause the actual results, financial condition, performance
or achievements of Basilea Pharmaceutica Ltd. to be materially different from
any future results, performance or achievements expressed or implied by such
forward-looking statements. Basilea Pharmaceutica Ltd. is providing this
communication as of this date and does not undertake to update any forward-
looking statements contained herein as a result of new information, future
events or otherwise.

For further information, please contact:

| Media Relations             | Investor Relations             |
| Peer Nils Schröder, PhD     | Barbara Zink, PhD, MBA         |
| Head Public Relations &     | Head Corporate Development     |
| Corporate Communications    |                                |
| +41 61 606 1102             | +41 61 606 1233                |
| [email protected] | [email protected] |
This press release can be downloaded from